Bedke J, Gouttefangeas C, Stenzl A
Klinik für Urologie, Eberhard Karls Universität Tübingen, Hoppe-Seyler-Straße 3, 72076 Tübingen, Deutschland.
Urologe A. 2012 Jan;51(1):44-9. doi: 10.1007/s00120-011-2712-6.
Immune therapy and tumor cell vaccination is a challenging option in prostate cancer therapy, especially as side effects rarely occur. This review highlights recent developments in vaccination therapy of prostate cancer. The FDA approved antigen presenting cell vaccine Sipuleucel-T is described and new strategies of immune therapy like RNA and peptide vaccination are discussed in detail. Currently the effect of prostate cancer vaccination has still limitations, at least partially due to the immune suppressive effects of the tumor microenvironment and regulatory T cells, which suppress the immune effector function. To overcome these hurdles the concept of immune checkpoint modulation, which has the aim to break tolerance mechanisms, is discussed. Potential clinical therapies of checkpoint modulation are outlined.
免疫疗法和肿瘤细胞疫苗接种在前列腺癌治疗中是一项具有挑战性的选择，尤其是因为副作用很少发生。本综述重点介绍了前列腺癌疫苗接种治疗的最新进展。描述了美国食品药品监督管理局（FDA）批准的抗原呈递细胞疫苗西普尤单抗-T，并详细讨论了免疫疗法的新策略，如RNA和肽疫苗接种。目前，前列腺癌疫苗接种的效果仍有局限性，至少部分原因是肿瘤微环境和调节性T细胞的免疫抑制作用，它们会抑制免疫效应功能。为了克服这些障碍，讨论了旨在打破耐受机制的免疫检查点调节概念。概述了检查点调节的潜在临床治疗方法。
